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Abstract
Anastomotic leakage (AL) is a well-known cause of morbidity after low anterior resection (LAR) for rectal cancer, but its impact on
oncologic outcome is not well understood. The aim of this study is to investigate the impact of AL on long-term oncologic outcome
and to identify factors associated with AL that may affect prognosis after LAR for rectal cancer.
A retrospective analysis of patients who underwent curative resection for rectal cancer without diverting stoma was performed. To
investigate AL related factors that may be associated with oncologic outcome, Clavien-Dindo grades, prognostic nutritional indices
(PNI) and inﬂammatory indices were included.
One hundred and one patients out of a total of 1258 patients developed postoperative AL, giving an AL rate of 8.0%. Patients with
AL showed poorer disease-free survival (DFS), than patients without AL (hazard ratio [HR]=1.6; 95% conﬁdence intervals [CI]:
1.1–2.5; P=0.01). In patients who developed AL, age over 60 (HR=2.2; 95% CI: 1.1–4.7; P=0.033), advanced pathologic stage
(HR=2.4; 95% CI: 1.4–4.0; P=0.001), suppressed neutrophil-proportion (80%) (HR=2.6; 95% CI: 1.2–5.8; P=0.019) and PNI
<36 (HR=3.5; 95% CI: 1.2–9.6; P=0.018) were associated with poorer DFS.
AL was associated with poorer DFS. In patients with AL, a suppressed neutrophil-proportion and decreased PNI below 36 were
associated with tumor recurrence.
Abbreviations: AL = anastomotic leakage, ASA grade = American society of anesthesiologists physical status grade, CEA =
carcinoembryonic antigen, CI= conﬁdence interval, DFS= disease-free survival, HR= hazard ratio, LAR= low anterior resection, OS
= overall survival, PNI = prognostic nutritional index.
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Anastomotic leakage (AL) is one of the major causes of morbidity
after low anterior resection (LAR) for rectal cancer, with reported
incidences ranging from 3.9% to 19.2%.[1–6] Introduction of
stapling anastomosis along with advancements in surgical
techniques have resulted in an increased number of sphincter
preserving rectal resections, however this has consequently
increased the likelihood of AL.[7–9]
It is evident that AL leads to short term morbidity, mortality,
and poor functional results.[10] There have been many efforts to
prevent AL by identifying high-risk patients. According to recentEditor: Adrian Billeter.
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1studies, male gender, preoperative chemo-radiotherapy, lower
tumor location as well as increased number of stapler application
for distal rectal transection have been established risk factors for
AL.[11–13] Although there seems to be an overall consensus that
AL is related to poor prognosis, the oncologic consequence in
patients with AL is uncertain. There are several contradictory
studies with respect to long-term and cancer-speciﬁc survival of
patients with AL. In a large-scale population-based cohort study,
AL was not associated with an increased local recurrence rate.[14]
A recent retrospective study using propensity score analysis also
reported that AL has no impact on long-term survival in both
overall and cancer-speciﬁc survival.[15] In contrast to these
reports, a multicenter study found an impaired overall survival
(OS) after AL, but there was no association with poorer cancer-
speciﬁc survival.[16] Another multicenter study analyzing the
impact of AL after total mesorectal excision for rectal cancer
demonstrated that AL resulted in inferior oncologic outcomes
with respect to both disease-free survival (DFS) and OS.[17]
Similarly, a recent meta-analysis of 21 trials concluded that AL
has a negative prognostic impact on local recurrence and cancer-
speciﬁc survival.[18] The discrepancy between previous reports
may reﬂect the heterogeneous nature of the prognosis after AL. In
this context, clarifying factors that affect the prognosis after AL
may have value to deﬁne subgroups of different prognosis, which
will in turn lead to a more tailored treatment strategy for
individual patients.
We have previously demonstrated that the clinical features of
AL are different according to whether open or minimal invasive
[11]
Noh et al. Medicine (2016) 95:30 Medicinesurgery is performed amongst other risk factors. This reﬂects
that variable physiologic and biochemical processes after
different surgical approaches may inﬂuence the clinical
manifestation of AL. In this context, we hypothesize that the
oncologic outcomes after AL may differ in relation to various
clinical, biochemical, and pathological factors. To investigate
this issue, we reviewed our patients’ characteristics and
compared the oncologic outcome between patients with and
without AL. We further analyzed the data to characterize
in detail the factors associated with poor outcomes in patients
with AL.2. Materials and methods
From January 2006 to December 2012, the medical records of
consecutive patients who underwent an elective operation of
LAR with colorectal anastomosis using the double-stapling
method for the treatment of rectal cancer at a high volume
tertiary medical institution were reviewed retrospectively. All
patients with a pathological diagnosis of rectal adenocarcinoma
located within 15cm from anal verge were included. Of 1961
patients diagnosed as rectal cancer and performed surgery under
curative intention, we excluded 426 patients who underwent
surgical procedures other than LAR with double stapling
anastomosis such as local excision, Hartmann’s operation,
hand-sewn coloanal anastomosis and abdominoperineal resec-
tion, as well as 278 patients who had a diverting stoma. We
deﬁned AL as the breakdown of a colorectal anastomosis with an
infected ﬂuid collection in the pelvic cavity within 60 days after
the index operation. AL was diagnosed by computed tomogra-
phy or by clinical symptoms and signs including change of drain
color and/or fever with peritonitis. As proximal diversion may
prevent the clinical manifestations of AL, patients who under-
went protective stoma formation were not included in this study.
The variables included in the analysis comparing patients with
and without ALwere as follows: age, gender, American society of
anesthesiologists (ASA) physical status grade, preoperative
carcinoembryonic antigen (CEA) level, surgical approach (open
surgery or minimal invasive surgery), pathologic stage, histologic
grade, lymphovascular invasion, local recurrence, pre- or
postoperative chemo-radiotherapy, interval from surgery to
initiation of postoperative adjuvant treatment, duration of
hospital stay after surgery, duration of follow-up, DFS and
OS. Minimal invasive surgery included both laparoscopic and
robotic surgery. Pathologic staging was based on the 7th edition
of the American Joint Commission on Cancer tumor-node-
metastasis (TNM) system.[19] Follow-up strategies for the
patients with and without AL were identical. Patients were
followed up every 6 months for the ﬁrst 3 years after surgery and
yearly thereafter. Each follow-up visit included a medical history,
a physical examination, and measurement of the serum CEA
concentration. Routine imaging studies consist of chest radiog-
raphy and computed tomography on chest, abdomen, and pelvis.
Chest radiography and abdominopelvic CT were performed 6
months after surgery for 3 years and annually thereafter.
Colonoscopy was performed annually after surgery. Ultrasonog-
raphy, whole-body bone scintigraphy and positron emission
tomography (PET) were performed when there was suspicion of
recurrence on routine imaging studies. Patients who experienced
AL underwent same follow-up schedule as patients without AL
after their treatment for AL was over. Local recurrence was
deﬁned as any recurrent tumor growth within the pelvic cavity or
perineal area conﬁrmed by clinical, radiological, or pathologic2evaluation, and the other tumor recurrence events were
categorized as systemic recurrences. DFS was deﬁned as months
from the date of surgery to the date of detection of recurrence, last
follow-up or death. OS was deﬁned as months from the date of
surgery to the date of death or last follow-up. Among these
variables, age, gender, ASA grade, surgical method, CEA,
pathologic stage, histologic grade, and lymphovascular invasion
were included in the survival analysis. Furthermore, we added
factors related to perioperative treatment modalities (pre- or
postoperative chemo-radiotherapy) into the analysis to adjust for
their effect on oncologic outcomes. In the patients who required
adjuvant treatment, postoperative chemo-radiotherapy was
performed by clinical oncologists and the timing of initiation
was determined considering patients’ recovery after surgery.
Patients received identical adjuvant chemotherapeutic regimen
regardless of the experience of AL. The interval between the index
operation and the initiation of postoperative adjuvant treatment
was categorized and analyzed to adjust for confounding. To
investigate the factors affecting oncologic outcomes in patients
with AL, we analyzed variables such as age, gender, ASA grade,
surgical method, CEA, pathologic stage, histologic grade, and
lymphovascular invasion. Additionally, the severity of the AL
according to the Clavien-Dindo classiﬁcation (grade I, deviation
from the normal postoperative course without the need for
therapy; grade II, complications requiring pharmacological
treatment; grade III, complications requiring surgical, endoscopic
or radiological intervention; grade IV, life-threatening compli-
cations requiring intensive care; and grade V, death), leukocyte
count, neutrophil-proportion (out of total leukocytes) and
prognostic nutritional index (PNI) were included as factors
assessing the clinical severity and degree of inﬂammatory or
immunologic reaction.[20] All of these biochemical indices were
assessed at the time of the diagnosis of AL. The PNI
was calculated according to the following formula: 10albumin
(g/dl) +0.005x total lymphocyte count (per mm3).[21] This study
was approved by the Institutional Review Board of Severance
Hospital (4-2016-0153).2.1. Statistical analysis
All statistical analyses were performed using SPSS Statistics
(version 20.0., IBM Corp., Armonk, NY), with the exception of
calculating cut-off value of PNI. Categorical variables were
analyzed using the x2 test and continuous variables were
analyzed using the Student t test. Differences in survival between
groups with and without AL were compared using the
Kaplan–Meier method and tested with the log-rank test. Factors
associated with DFS and OS were analyzed by a Cox-
proportional hazards regression model. For the Cox-proportion-
al hazards regression, continuous variables were dichotomized
according to the clinical implications or using the mean value of
each variable as the cut-off value. Optimal cut-off value of PNI
regarding patient prognosis were assessed bymeans of maximally
selected log-rank statistics using the Maxstat package of R
software (version 3.2.2., R Foundation for Statistical Computing,
Vienna, Austria).[22] Parameters of perioperative treatment with
5 categories were dummy coded to allow independent entry into
the ﬁnal model. All variables in the risk set were assessed as
putative prognostic factors for DFS and OS in unadjusted Cox-
regression. Variables with a P value of less than 0.10 in the
unadjusted Cox regression were selected for risk-adjusted Cox-
regression. A P value of less than 0.05 was considered statistically
signiﬁcant.
Table 1
Characteristics of overall patients.
Non-AL
∗
(n=1157)
AL
(n=101) P
Age, mean (±SD), y 60.8 (±11.0) 57.5 (±11.0) 0.003
Gender <0.001
Male 691 (59.7%) 79 (78.2%)
Female 466 (40.3%) 22 (21.8%)
ASA† grade 0.370
I 712 (61.5%) 56 (55.4%)
II 413 (35.7%) 43 (42.6%)
III 32 (2.8%) 2 (2.0%)
Preoperative CEA‡, mean (±SD), ng/mL 8.9 (±36.2) 8.8 (±26.2) 0.981
Surgical method 0.001
Open surgery 401 (34.7%) 19 (18.8%)
Minimal invasive surgery 756 (65.3%) 82 (81.2%)
Pathologic stage 0.504
0 26 (2.2%) 0 (0.0%)
I 327 (28.3%) 29 (28.7%)
II 307 (26.5%) 30 (29.7%)
III 400 (34.6%) 36 (35.6%)
IV 97 (8.4%) 6 (5.9%)
Histologic grade 0.728
I 192 (16.8%) 18 (17.8%)
II 899 (78.6%) 80 (79.2%)
III 53 (4.6%) 3 (3.0%)
Lymphovascular invasion 0.142
Present 830 (73.5%) 81 (80.2%)
Absent 299 (26.5%) 20 (19.8%)
Systemic recurrence 0.732
Present 202 (17.5%) 19 (18.8%)
Absent 995 (82.5%) 82 (81.2%)
Local recurrence 0.002
Present 55 (4.8%) 12 (11.9%)
Absent 1102 (95.2%) 89 (88.1%)
Preoperative chemo-radiotherapy 0.031
Present 170 (14.7%) 23 (22.8%)
Absent 987 (85.3%) 78 (77.2%)
Postoperative chemo-radiotherapy 0.656
Present 702 (60.7%) 59 (58.4%)
Absent 455 (39.3%) 42 (41.6%)
Adjuvant treatment intervalx,
mean (±SD), d
27.6 (±11.8) 42.1 (±17.9) <0.001
Postoperative hospital stay,
mean (±SD), d
10.9 (c6.7) 23.0 (±13.9) <0.001
SD = standard deviation.
∗
AL: anastomotic leakage.
† ASA: American society of anesthesiologists.
‡ CEA: carcinoembryonic antigen.
x Adjuvant treatment interval: Interval between surgery and initiation of postoperative adjuvant
treatment.
Noh et al. Medicine (2016) 95:30 www.md-journal.com3. Results
A total of 1258 patients were included in the analysis and their
mean follow-up period was 49.5 (±24.2) months. Among these
patients, 101 patients developed postoperative AL, giving an AL
rate of 8.0%. We compared the two groups of 1157 patients
without AL versus 101 patients with AL. The comparisons of the
characteristics between 2 groups are summarized in Table 1.
Patients with AL were younger than those without AL (P=
0.003). There were moremale patients and a higher proportion of
patients undergoing minimal invasive surgery in AL group
compared with the non-AL group (P<0.001, P=0.001).
Comparing the pattern of recurrences, there was no signiﬁcant
difference for the incidence of systemic recurrence between two
groups. However, the incidence of local recurrence was higher in
AL group (11.9% vs. 4.8%, P=0.002). Patients in AL group
received more preoperative chemo-radiotherapy (P=0.031) and
had a longer interval between surgery and postoperative adjuvant
treatment compared with patients without AL (P<0.001).
Patients with AL also had a longer hospital stay (P<0.001).
There were no signiﬁcant differences between patients with and
without AL in other variables such as ASA grade, preoperative
CEA level, pathologic stage, histologic grade, lymphovascular
invasion, and postoperative chemo-radiotherapy.
With regards to DFS, there was a signiﬁcant difference between
the patients with and without AL (P=0.011) (Fig. 1A). Patients
with AL had a 3-year DFS of 69.8% and 5-year DFS of 56.1%.
Patients without AL had 3-year DFS of 78.0% and 5-year DFS of
76.1%. In OS, there was no signiﬁcant difference between these
two groups (P=0.530) (Fig. 1B). Patients with AL had 3-year and
5-year OS of 87.3% and 80.3%, respectively. Patients without
AL had 3-year and 5-year OS of 90.4% and 83.5%, respectively.
In the unadjusted Cox-proportional hazards regression, AL was
found to be a poor prognostic factor for DFS (hazard ratio
[HR]=1.6; 95% conﬁdence intervals [CI]: 1.1–2.3; P=0.012).
Other variables that were associated with poorer DFS included
surgical approach, preoperative CEA level, pathologic stage,
histologic grade, lymphovascular invasion, and perioperative
treatment. After adjusting for potential confounding factors in
the risk-adjusted Cox-regression analysis, AL was conﬁrmed to
have a statistically signiﬁcant inﬂuence on DFS (HR=1.6; 95%
CI: 1.1–2.4; P=0.012), along with other factors such as elevated
preoperative CEA (HR=1.3; 95% CI: 1.0–1.7; P=0.026),
advanced pathologic stage (HR=2.6; 95% CI: 2.1–3.1; P<
0.001) and presence of lymphovascular invasion (HR=1.6; 95%
CI: 1.2–2.0; P=0.001) (Table 2).
The indices reﬂecting clinical severity and degree of inﬂamma-
tion or immunologic reaction are summarized in Table 3. Among
the 101 patients with AL, there were 17 (16.8%), 57 (56.4%),
and 27 (26.7%) patients with severities of Clavien-Dindo grade
2, 3, and 4, respectively. Thirty-four (36.2%) patients had raised
leukocyte count (>11,000/mm3) with the other 67 patients
(63.8%) not showing biochemical evidence of leukocytosis.
Seventy patients (69.3%) showed an increased neutrophil-
proportion above normal levels (>80%). For the PNI, the cut-
off point in relation to DFS was calculated as 36. There were 29
patients (28.7%) with a PNI above 36. In the unadjusted Cox-
proportional hazards regression, Clavien-Dindo grade of AL,
neutrophil–proportion, and PNI were not associated with risk of
recurrence (HR=1.0; 95% CI: 0.6–1.7; P=0.992, HR=1.9;
95% CI: 0.9–3.8; P=0.085, HR=2.6; 95% CI: 1.0–6.8; P=
0.051). Suppressed leukocyte count was associated with
increased risk of recurrence (HR=2.6; 95% CI: 1.0–6.5; P=30.04). However, after adjusting for potential confounding factors
in the risk-adjusted Cox-regression analysis, suppressed neutro-
phil-proportion and decreased PNI were found to have a
statistically signiﬁcant relationship with DFS (HR=2.6; 95%
CI: 1.2–5.8; P=0.02, HR=3.5; 95% CI: 1.2–9.6; P=0.02),
along with the other factors of age over 60 (HR=2.2; 95% CI:
1.1–4.7; P=0.033) and advanced pathologic stage (HR=2.4;
95% CI: 1.4–4.0; P=0.001) (Table 4). In the Cox-proportional
hazards regression for OS, no biochemical indices were
associated with OS. Age over 60 (HR=6.4; 95% CI:
1.8–23.7; P=0.005) and advanced pathologic stage (HR=4.1;
95% CI: 1.6–10.7; P=0.004) were associated with poor OS
(Table 5).
Figure 1. Kaplan–Meier curve for disease free survival and overall survival in patients with (green line) and without (blue line) anastomotic leakage: A. Comparison of
disease free survival between (P=0.011). B. Comparison of overall survival (P=0.530).
Table 2
Factors associated with disease-free survival of overall patients.
Univariate analysis Multivariate analysis
Hazard ratio (95% CI
∗
) P Hazard ratio (95% CI) P
Age (>60 years) 0.997 (0.791–1.256) 0.987
Gender (female) 0.839 (0.659–1.069) 0.155
ASA† grade (II, III) 1.234 (0.976–1.561) 0.079 1.121 (0.877–1.434) 0.362
Surgical method 0.001 0.642
Open surgery 1 1
Minimal invasive surgery 0.670 (0.530–0.847) 0.942 (0.732–1.212)
CEA‡ (>5ng/mL) 2.160 (1.700–2.744) <0.001 1.336 (1.035–1.725) 0.026
Pathologic stage 2.673 (2.324–3.075) <0.001 2.581 (2.122–3.141) <0.001
Histologic grade 1.741 (1.327–2.283) <0.001 1.228 (0.916–1.648) 0.170
Lymphovascular invasion (present) 2.527 (1.998–3.197) <0.001 1.561 (1.203–2.024) 0.001
Anastomotic leakage (present) 1.617 (1.113–2.349) 0.012 1.646 (1.118–2.423) 0.012
Perioperativex treatment <0.001 0.003
Not indicated to treatment 1 1
Preoperative chemo-radiotherapy 6.193 (3.843–9.982) 1.013 (0.527–1.946)
Postoperativejj chemo-radiotherapy within 4 weeks 4.089 (2.606–6.416) 0.558 (0.303–1.026)
Postoperativejj chemo-radiotherapy beyond 4 weeks 5.346 (3.329–8.587) 0.636 (0.336–1.202)
Refuse to treatment 4.318 (2.406–7.750) 0.950 (0.483–1.869)
∗
CI: conﬁdence interval.
† ASA: American society of anesthesiologists.
‡ CEA: carcinoembryonic antigen.
x Perioperative treatment: modality of pre- or postoperative chemo-radiotherapy.
jj Postoperative chemo-radiotherapy within or beyond 4 weeks: Initiation of postoperative adjuvant treatment within or beyond 4 weeks after surgery.
Table 3
Clinical severity indices of patients with anastomotic leakage.
N=101
Clavien-Dindo grade
2 17 (16.8%)
3 57 (56.4%)
4 27 (26.7%)
Leukocyte count
11,000/mm3 67 (63.8%)
>11,000/mm3 34 (36.2%)
Proportion of neutrophil in total leukocyte
80% 31 (30.7%)
>80% 70 (69.3%)
Prognostic nutritional index
36 72 (71.3%)
>36 29 (28.7%)
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44. Discussion
In our study, 8.0% of patients developed AL after LAR without
protective stoma, which is similar to the results of previous
reports.[1–6] The key ﬁnding of this study is that patients with AL
show increased risk of tumor recurrence compared with patients
without AL. Furthermore, in patients with AL, inﬂammatory
indices such as neutrophil-proportion and PNI are associated
with poor oncologic outcomes. Interestingly, there was no
signiﬁcant difference of OS between patients with and without
AL. This might be result of adequate post-recurrence manage-
ment that consisted of curative resection and sequential
chemotherapy for resectable recurrence and intensive chemo-
therapy and/or radiotherapy for unresectalbe recurrence.
Although the pathogenesis of the association between AL and
tumor recurrence remains uncertain, several authors have
suggested various possible hypotheses: one suggested mechanism
Table 4
Factors associated with disease-free survival of patients with anastomotic leakage.
Univariate analysis Multivariate analysis
Hazard ratio (95% CI
∗
) P Hazard ratio (95% CI) P
Age (>60 years) 2.048 (1.007–4.163) 0.048 2.247 (1.066–4.739) 0.033
Gender (female) 1.074 (0.688–1.678) 0.754
ASA† grade (II, III) 0.649 (0.311–1.356) 0.25
Surgical method 0.764
Open surgery 1
Minimal invasive surgery 0.878 (0.376–2.053)
CEA‡ (>5ng/mL) 1.959 (0.949–4.044) 0.069 1.687 (0.746–3.819) 0.209
Pathologic stage 2.181 (1.401–3.393) 0.001 2.362 (1.396–3.994) 0.001
Histologic grade 2.326 (0.896–6.038) 0.083 1.314 (0.397–4.355) 0.655
Lymphovascular invasion (present) 1.390 (0.621–3.112) 0.424
Clavien-Dindo grade of anastomotic leakage 0.997 (0.573–1.734) 0.992
Leukocyte (11,000/mm3) 2.601 (1.037–6.524) 0.042 1.407 (0.507–3.907) 0.512
Proportion of neutrophil in total leukocyte (80%) 1.876 (0.917–3.839) 0.085 2.600 (1.167–5.795) 0.019
Prognostic nutritional index (36) 2.598 (0.996–6.776) 0.051 3.456 (1.240–9.633) 0.018
xPerioperative treatment 0.195
Not indicated to treatment 1
Preoperative chemo-radiotherapy 4.240 (1.143–15.730)
Postoperative chemo-radiotherapy within 6 weeksjj 2.857 (0.795–10.270)
Postoperative chemo-radiotherapy beyond 6 weeksjj 3.138 (0.830–11.856)
∗
CI: conﬁdence interval.
† ASA: American society of anesthesiologists.
‡ CEA: carcinoembryonic antigen.
x Perioperative treatment: modality of pre- or postoperative chemo-radiotherapy.
jj Postoperative chemo-radiotherapy within or beyond 4 weeks: initiation of postoperative adjuvant treatment within or beyond 4 weeks after surgery.
Noh et al. Medicine (2016) 95:30 www.md-journal.comis that remnant intraluminal tumor cells can disseminate through
the leakage site into the peritoneum, thus increasing tumor
recurrence rates.[23–25] In vitro and experimental animal models
demonstrate that viable cancer cells detected in the bowel lumen
and on suture or staple lines during surgery retain signiﬁcant
growth andmetastatic potential.[23,26–29] Inadvertent perforationTable 5
Factors associated with overall survival of patients with anastomotic
Univari
Hazard ratio (95%
Age (>60 years) 3.634 (1118–11.80
Gender (female) 0.917 (0.0.453–1.4
ASA† grade (II, III) 0.745 (0.244–2.28
Surgical method
Open surgery 1
Minimal invasive surgery 0.582 (0.179–1.89
CEA‡ (>5ng/mL) 2.962 (0.994–8.82
Pathologic stage 3.083 (1.414–6.72
Histologic grade 2.951 (0.641–13.5
Lymphovascular invasion (present) 1.561 (0.480–5.08
Clavien-Dindo grade of anastomotic leakage 1.037 (0.431–2.49
Leukocyte (11,000/mm3) 3.053 (0.675–13.8
Proportion of neutrophil in total leukocyte (80%) 1.845 (0.620–5.49
Prognostic nutritional index (36) 1.696 (0.466–6.17
Perioperativex treatment
Not indicated to treatment 1
Preoperative chemo-radiotherapy 7.252 (0.800–65.6
Postoperative chemo-radiotherapy within 6 weeksjj 1.923 (0.200–18.5
Postoperative chemo-radiotherapy beyond 6 weeksjj 4.638 (0.541–39.7
∗
CI: conﬁdence interval.
† ASA: American society of anesthesiologists.
‡ CEA: carcinoembryonic antigen.
x Perioperative treatment: modality of pre- or postoperative chemo-radiotherapy.
jj Postoperative chemo-radiotherapy within or beyond 4 weeks: Initiation of postoperative adjuvant treatm
5of the bowel during surgery has been associated with a
signiﬁcantly higher local recurrence rate and reduced overall
survival.[30,31] These ﬁndings support the notion that AL may
lead to extra-luminal implantation of exfoliated cancer cells from
the bowel lumen.[18] Another proposed mechanism is that the
systemic inﬂammatory response syndrome caused by AL mayleakage.
ate analysis Multivariate analysis
CI
∗
) P Hazard ratio (95% CI) P
9) 0.032 6.436 (1.750–23.662) 0.005
74) 0.502
1) 0.607
0.37
9)
4) 0.051 2.580 (0.836–7.964) 0.099
1) 0.005 4.086 (1.554–10.747) 0.004
81) 0.165
2) 0.459
6) 0.935
16) 0.147
3) 0.271
8) 0.423
0.177
99)
10)
80)
ent within or beyond 4 weeks after surgery.
[32] [33]
Noh et al. Medicine (2016) 95:30 Medicineplay an important role in survival. McArdle et al noted the
systemic inﬂammatory response syndrome may stimulate
proliferation and metastasis in residual tumor cells. The release
of pro-inﬂammatory cytokines and growth factors as part of the
systemic inﬂammatory response secondary to intra-abdominal
sepsis and associated immune suppression may have a direct
effect on the growth of residual tumor cells.[34–36] In our study,
we adopted leukocyte count, neutrophil –proportion and PNI as
biochemical indices, which were effective and easy-to use serum
indicators. Leukocyte count and neutrophil-proportion are
traditional indices to estimate the inﬂammatory reaction. PNI,
which is calculated based on the serum albumin concentration
and total lymphocyte count, is thought to be a simple and useful
parameter to determine the immunological and nutritional status
of patients.[21] On multivariate analysis for DFS, suppressed
neutrophil-proportion and decreased PNI was associated with
increased risk of tumor recurrence. Intra-abdominal sepsis-
induced immunosuppression could alter the natural activity of
immune system against inﬂammation. This altered immunity may
appear as suppressed neutrophil-proportion and cause incom-
plete tumor suppression.
Comparing the interval between surgery and postoperative
adjuvant treatment as well as the duration of hospital stay after
surgery, there were signiﬁcant differences between patients with
and without AL in this study. These results of delays in initiation
of adjuvant treatment and in patients’ recovery are frequent
events in patients who develop AL. Due to the possibility of these
delays inﬂuencing oncologic outcome, we included it as a
confounding factor along with preoperative chemo-radiotherapy
in the multivariate analysis for survival.[37,38]
We acknowledge the limitations of the present study. By its
retrospective nature, there may be uncontrollable and unrecog-
nized biases: for example, in our analysis, patients without AL
were of an older age than patients with AL. This result may be due
to the selection of patients for fecal diversion. Patients with old
age and poor general health are more likely to have undergone
fecal diversion, as this would prevent the potential severe clinical
manifestations of AL as well as the consequent requirement for
reoperation.[39,40] Also in our study, patients with protective
stoma were excluded to clarify the diagnosis of AL and it is the
likely reason why the patients with AL were of younger age.
Meanwhile, the number of patients with AL was quite low than
without AL. This unmatched comparison might have possible
risk for bias. However, it was unavoidable in this observational
study and over 100 of patients with AL had enough strength for
statistical analysis. Also, multivariate analysis for the major end
point of oncologic outcome was performed to reduce the risk of
bias. Despite these limitations, however, this study has provided
unique analyses of details of factors such as the severity of AL, the
interval between surgery and postoperative chemo-radiotherapy
along with known putative prognostic factors. These compre-
hensive analyses consider not only the severity of the systemic
inﬂammatory response of AL but also the consequent adverse
outcome of delayed postoperative adjuvant treatment which may
provide further insight into the treatment of rectal cancer.
Certainly, further studies will be required to further advance our
knowledge of the oncological consequences of AL to better help
with management of such patients.
5. Conclusions
AL was associated with poor oncologic outcomes, especially in
DFS. In patients with AL, besides the established poor prognostic6factors such as age over 60 and advanced pathologic stage, a
suppressed neutrophil-proportion as well as a decreased PNI
below 36 were associated with tumor recurrence.References
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